Wuhan Hiteck Biological Pharma Co.,Ltd (SHE:300683)

Market Cap	3.42B +14.4%
Revenue (ttm)	543.82M -19.3%
Net Income	-240.38M
EPS	-1.83
Shares Out	130.89M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	5,670,900
Open	28.10
Previous Close	27.52
Day's Range	25.94 - 28.10
52-Week Range	24.56 - 61.76
Beta	-0.30
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 26, 2026

About SHE:300683

Wuhan Hiteck Biological Pharma Co.,Ltd, a biopharmaceutical company, engages in the research and development, production, and sale of bio engineering products and freeze-dried powder injection in China. Its products include Epramine for injection; mouse nerve growth factor for injection; Anewway, a mouse nerve growth factor for injection; omeprazole sodium for injection, an alternative therapy for duodenal ulcer, gastric ulcer, reflux esophagitis, and Zollinger-Ellison syndrome; adenosine cyclophosphate for injection that is used for angina pec...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1992
• Employees: 1,309
• Stock Exchange: Shenzhen Stock Exchange
• Ticker Symbol: 300683

Financial Performance

In 2025, SHE:300683's revenue was 541.45 million, a decrease of -16.57% compared to the previous year's 648.97 million. Losses were -231.27 million, 233.5% more than in 2024.